Enveric Biosciences (ENVB) Receivables (2015 - 2020)
Enveric Biosciences (ENVB) posted Receivables of $7.6 million for Q3 2020, up 3.69% sequentially from $7.3 million in Q2 2020, and down 0.6% YoY from $7.6 million in Q4 2019.
Enveric Biosciences (ENVB) Receivables (2015 - 2020) Analysis & Trends
Enveric Biosciences has reported Receivables for 6 years, with the latest figure at $7.6 million in Q3 2020.
- Quarterly Receivables fell 0.6% year-over-year to $7.6 million in Q3 2020, while the trailing twelve-month figure through Sep 2020 was $7.6 million (down 0.6% YoY) and the FY2019 annual result came in at $6.4 million, down 18.89% from the prior year.
- Receivables grew to $7.6 million in Q3 2020 per ENVB's latest filing, from $7.3 million in the prior quarter.
- Over five years, Receivables peaked at $9.6 million in Q1 2017 and troughed at $4.1 million in Q2 2016.
- A 5-year average of $7.8 million and a median of $7.9 million in 2018 frame the typical range for Receivables.
- The sharpest annual moves came in 2017 and 2019: Receivables soared 110.96% in 2017, then fell 18.89% in 2019.
- Over 5 years, Receivables stood at $8.1 million in 2016, then gained by 9.66% to $8.8 million in 2017, then dropped by 10.94% to $7.9 million in 2018, then dropped by 18.89% to $6.4 million in 2019, then advanced by 18.47% to $7.6 million in 2020.
- According to Business Quant data, Receivables over the past three periods registered $7.6 million, $7.3 million, and $8.1 million for Q3 2020, Q2 2020, and Q1 2020 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 7.56 Mn |
| Jun 30, 2020 | 7.29 Mn |
| Mar 31, 2020 | 8.10 Mn |
| Dec 31, 2019 | 6.38 Mn |
| Sep 30, 2019 | 7.61 Mn |
| Jun 30, 2019 | 8.54 Mn |
| Mar 31, 2019 | 8.90 Mn |
| Dec 31, 2018 | 7.87 Mn |
| Sep 30, 2018 | 7.83 Mn |
| Jun 30, 2018 | 7.94 Mn |
| Mar 31, 2018 | 8.46 Mn |
| Dec 31, 2017 | 8.84 Mn |
| Sep 30, 2017 | 9.17 Mn |
| Jun 30, 2017 | 8.72 Mn |
| Mar 31, 2017 | 9.59 Mn |
| Dec 31, 2016 | 8.06 Mn |
| Sep 30, 2016 | 7.72 Mn |
| Jun 30, 2016 | 4.13 Mn |
| Mar 31, 2016 | 4.93 Mn |
| Dec 31, 2015 | 4.87 Mn |